Clinical utility of a blood-based BRAF(V600E) mutation assay in melanoma.


BRAF inhibitors (BRAFi) have led to clinical benefit in patients with melanoma. The development of a blood-based assay to detect and quantify BRAF levels in these patients has diagnostic, prognostic, and predictive capabilities that could guide treatment decisions. Blood BRAF(V600E) detection and quantification were performed on samples from 128 patients… (More)
DOI: 10.1158/1535-7163.MCT-14-0349


  • Presentations referencing similar topics